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“…there is accumulating evidence that treatment outcome in chronic 
lymphocytic leukemia can be influenced by germline polymorphisms 
that affect drug disposition and/or pharmacodynamics, and that these 
effects may explain some of the variability in treatment outcome that 
cannot be explained by genotypic and phenotypic variation of the 
malignant clone.”
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Chronic lymphocytic leukemia (CLL) is a 
commonly occurring leukemia in adults. It 
results from a clonal expansion of antigen-
experienced mature B-cells and is character-
ized by a chronic relapsing course requiring 
multiple different treatment regimens and 
frequently culminating in therapy resistance. 
For a number of years the single most impor-
tant clinical decision tool in the treatment 
of CLL has been the presence or absence of 
p53 protein defects caused by deletion and/or 
mutation of the TP53 gene on chromosome 
17p. These defects, which result in chemo-
resistance, are associated with the worst 
prognosis in CLL. TP53 defects are found 
in approximately 10% of newly diagnosed 
patients and approximately 50% of patients 
with chemorefractory disease [1].
For those patients possessing a TP53 dele-
tion, many authorities recommend avoidance 
of chemotherapy-based treatments in favor 
of drugs that do not depend on p53 for their 
action, such as the anti-CD52 monoclonal 
antibody alemtuzumab and high-dose gluco-
corticoids, such as methylprednisolone, either 
alone or in combination. This approach illus-
trates the application of stratified medicine in 
CLL therapy.
For the majority of CLL patients who do 
not possess a TP53 deletion, the front-line 
treatment regimen of choice is chemotherapy 
with fludarabine plus cyclophosphamide 
(FC) in combination with the anti-CD20 
monoclonal antibody rituximab (FCR) [2]. 
However, FCR is appropriate only for those 
patients who are considered sufficiently fit to 
tolerate the toxicity of this drug combination. 
Patients without TP53 defects and consid-
ered unfit for FCR are treated less intensively 
with chlorambucil or bendamustine, usually 
in combination with rituximab [3,4].
Irrespective of which drug regimen patients 
receive, the efficacy and toxicity of treatment 
varies widely between individual patients. 
For example, in the pivotal GCLLSG CLL8 
trial that demonstrated the benefit of adding 
rituximab to FC chemotherapy, the complete 
response rate was 44%, with 56% of patients 
experiencing significant hematological toxic-
ity [2]. Although some of this variation in sen-
sitivity to FCR can be explained by genotypic 
and phenotypic variation within the malig-
nant clone, it is possible that treatment out-
come is also influenced by germline polymor-
phisms in genes that affect drug disposition 
and pharmacodynamics.
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Fludarabine is a purine analogue that undergoes 
intracellular phosphorylation to its active 5´  triphos-
phate form in order to exert its cytotoxic effects [5]. 
This phosphorylation step is primarily carried out by 
DCK [5]. A number of SNPs have been identified in 
the DCK gene, and some of these have been shown to 
influence the expression and/or activity of the corre-
sponding protein, or have been associated with clinical 
outcome. For example, a synonymous SNP (p.A100A) 
in the DCK gene has been associated with altered tox-
icity in patients with follicular lymphoma following 
treatment with FCR [6]. Additionally, cellular influx 
and efflux of fludarabine has been demonstrated to be 
mediated by a number of different transporters, includ-
ing hCNT2, hCNT3, hENT1, hENT2, ABCG2 and 
ABCC4. Polymorphisms within the genes encoding 
these transporters have been shown to confer altered 
function and therefore have the potential to influence 
transport and bioavailability of nucleoside analogues 
including fludarabine [7].
The alkylating agent cyclophosphamide requires 
conversion to its active metabolite 4-hydroxycyclo-
phophamide to exert its cytotoxic action. This activa-
tion involves a number of hepatic CYP450 isoforms, 
including CYP2B6, CYP2C9 and CYP3A4, with 
CYP2B6 thought to make the major contribution to 
this step [8]. The CYP2B6 gene is highly polymorphic 
with over 100 known SNPs identified in humans, 
which have differential frequencies across ethnicities, 
and in some confer alterations in CYP2B6 expression 
and function [9]. In our recent publication, we demon-
strated that the CYP2B6*6 allelotype (SNPs 516G>T 
and 785A>G) was associated with inferior response 
and more adverse events among patients with CLL who 
received FC in the LRF CLL4 trial [10]. This was the 
first demonstration that host pharmacogenetics can 
have a significant effect on the efficacy and toxicity of 
CLL therapy.
Rituximab acts by eliminating CD20+ B cells. Its 
cytotoxic effects are mediated by three different mech-
anisms: antibody-dependent cell-mediated cytotoxic-
ity, complement-dependent cytotoxicity and induction 
of apoptosis as a direct result of antigen engagement 
[11]. Genetic variation in components of these path-
ways has the potential to influence the effects of ritux-
imab. For example, antibody-dependent cell-mediated 
cytotoxicity requires the involvement of Fc gamma 
receptors on natural killer cells to induce death of the 
tumor cell, and polymorphisms in Fc gamma recep-
tor genes have been linked to the clinical response to 
rituximab in different disease settings. In particular, a 
non synonymous SNP in the FCGR2A gene (p.H131R) 
has been shown to predict response to rituximab-
containing regimens in patients with non-Hodgkin’s 
lymphoma. However, investigation of this SNP and 
another in FCGR3A (p.F176V) in the REACH trial 
failed to show any impact of these SNPs on response 
or survival rates in patients with relapsed CLL who 
received FCR [12]. With regard to complement-depen-
dent cyto toxicity, the antitumor activity of rituximab 
is abolished in mice deficient in C1q, which triggers 
activation of the complement cascade [13]. The C1QA 
gene contains several SNPs that have been shown to 
impact on rituximab action in a number of hematologi-
cal malignancies. For example, in follicular lymphoma, 
the C1QA c.A276G polymorphism was shown to affect 
therapeutic response and response duration following 
treatment with single-agent rituximab [14]. The effi-
cacy and toxicity of rituximab might also be affected 
by polymorphisms that have the potential to influence 
pharmacodynamics. For example, over 500 SNPs have 
been described in the gene encoding the rituximab tar-
get antigen, CD20. Although the frequency and func-
tion of these SNPs is largely unknown, one study dem-
onstrated an association between a SNP in exon 2 and 
therapeutic response to rituximab, cyclophosphamide, 
hydroxyldaunorubicin (doxorubicin), oncovin (vincis-
tine) and prednisone/prednisolone (R-CHOP) com-
bination therapy in patients with diffuse large B-cell 
lymphoma [10].
Germline polymorphisms might also influence the 
efficacy and toxicity of chemotherapy drugs used in 
patients considered unfit for FCR. In particular, gluta-
thione-S-transferases (GSTs) add glutathione to electro-
philic compounds such as chorambucil, leading to their 
detoxification, and overexpression of GSTP1 is believed 
to be an important mechanism in tumor cell resistance 
to alkylating agents. GSTP1 is known to be polymor-
phic, and variants of this enzyme have been shown to 
catalyze glutathione conjugation of chlorambucil with 
different levels of efficiency [15].
Bendamustine is an alkylating agent that is exten-
sively metabolized via hydrolytic and conjugative path-
ways to form metabolites with low cytotoxic activity. 
Major metabolites have low cytotoxic activity whereas 
two active minor metabolites, g-hydroxybendamustine 
(M3) and N-desmethylbendamustine (M4) are pri-
marily formed via CYP1A2 [16]. The concentrations 
of the active metabolites are low compared with the 
parent compound, suggesting that the majority of 
“The therapeutic landscape in chronic 
lymphocytic leukemia is about to be transformed 
owing to the advent of highly effective small-
molecule inhibitors, such as ibrutinib and 
idelalisib, which target components of the B-cell 
receptor signaling pathway.”
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the cytotoxic activity of is due to bendamustine itself. 
There are wide interindividual differences in CYP1A2 
expression and activity in humans, probably as a result 
of both genetic and environmental factors. Indeed, 
more than 15 variant CYP1A2 alleles and many more 
subvariants have been identified, and many of these 
have been associated with altered drug clearance or 
response as well as disease susceptibility [17].
Polymorphisms also have the potential to affect 
the pharmacodynamics of therapeutic glucocorticoids 
such as methylprednisolone. Indeed, small-scale stud-
ies in healthy volunteers have demonstrated a potential 
association between a nonsynonymous SNP of the his-
tamine HNMT gene (p.T105I) and variable suppres-
sion of cortisol secretion [18]. It is plausible that the 
altered glucocorticoid pharmacodynamics associated 
with this genetic polymorphism could translate into a 
clinically significant effect in CLL patients receiving 
methylprednisolone.
The therapeutic landscape in CLL is about to be trans-
formed owing to the advent of highly effective small-
molecule inhibitors, such as ibrutinib [19] and idelalisib 
[20], which target components of the B-cell receptor sig-
naling pathway. Although these drugs are characterized 
by their high efficacy and low toxicity, not all patients 
respond, and some have to discontinue treatment owing 
to adverse drug reactions. As with chemotherapeutic 
agents and monoclonal antibodies, the efficacy and tox-
icity of small-molecule inhibitors has the potential to be 
influenced by germline polymorphisms that influence 
drug disposition and/or pharmacodynamics.
In summary, there is accumulating evidence that 
treatment outcome in CLL can be influenced by 
germline polymorphisms that affect drug disposition 
and/or pharmacodynamics, and that these effects 
may explain some of the variability in treatment 
outcome that cannot be explained by genotypic and 
phenotypic variation of the malignant clone. Further 
investigation for associations between polymorphisms 
and treatment outcome could, with proper valida-
tion, provide clinicians with pharmacogenomic tools 
to allow greater patient stratification and ultimately 
more effective treatment.
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